ECS modulator (research)
Nabiximols
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Aliases.Sativex · GW-1000 · THC:CBD 1:1
A 1:1 THC:CBD oromucosal spray for spasticity in multiple sclerosis.
Updated on
Level of detail
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Identifiers
- Formula
- C₄₂H₆₀O₄
- Molar mass
- 628.90 g·mol⁻¹
- CAS
- 56575-23-6
- PubChem CID
- 9852188
- First described
- Développé dans les années 2000 par le laboratoire britannique GW Pharmaceuticals, qui obtient les premières autorisations à partir de 2005 (Canada) puis en Europe.
- Origin
- A medicine of plant origin: a purified extract of the flowers and leaves of Cannabis sativa, standardised to combine Δ9-THC and cannabidiol (CBD) in a ratio of about 1:1.
- InChIKey
- SSNHGLKFJISNTR-DYSNNVSPSA-N
In plain terms
Nabiximols (Sativex) is a medicine in oromucosal spray form combining equal parts of the THC and the CBD of cannabis, prescribed for spasticity in multiple sclerosis.
Receptors and activity
- CB1Partial agonist
- CB2Partial agonist
- CB1Modulator
- Agonist
- Partial agonist
- Antagonist
- Modulator
- Inverse agonist
Hover over a row for the precise value (Ki, EC50…)
Subjective signature
Hover over an axis to read its definition.
- Calm55
- Clarity25
- Sleep45
- Appetite40
- High45
Editorial estimate, not clinical.
Pharmacology
Nabiximols, marketed under the name Sativex, is a standardised pharmaceutical extract of Cannabis sativa combining Δ9-THC and cannabidiol in a ratio close to 1:1, presented as an oromucosal spray. THC acts as a partial agonist at the CB1 and CB2 receptors, while CBD behaves as a negative allosteric modulator of CB1 and appears to attenuate the psychotropic effects of THC; the two components are held to act in a complementary manner. In France it holds a marketing authorisation (2014) for moderate to severe spasticity in multiple sclerosis, without having been marketed, and it remains classified as a narcotic.
Origin (research tool)
Route of production: nabiximols is not a single molecule but a standardised pharmaceutical extract. Two chemotypes of Cannabis sativa, one rich in Δ9-THC, the other rich in CBD, are grown separately and then extracted; the two extracts are combined and titrated to set a THC:CBD ratio close to 1:1, formulated as an oromucosal spray.
Legal framework
France
A medicine classified as a narcotic. A marketing authorisation (AMM) was granted by the ANSM on 8 January 2014 for moderate to severe spasticity in multiple sclerosis where other treatments have failed, with initial prescription restricted to neurologists and rehabilitation specialists. The product has not, however, been marketed in France, in the absence of agreement on price. The Δ9-THC it contains moreover falls under the narcotics regime.
European Union
Authorised in several member states (Germany, Spain, Italy, etc.) as a prescription medicine for spasticity related to multiple sclerosis; narcotic status governs its dispensing.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Structural classification
- Class
- ECS modulator (research)
- Origin
- A medicine of plant origin: a purified extract of the flowers and leaves of Cannabis sativa, standardised to combine Δ9-THC and cannabidiol (CBD) in a ratio of about 1:1.
Association fixe de deux cannabinoïdes végétaux : un phytocannabinoïde de type dibenzopyrane (Δ9-THC) et un cannabinoïde de type résorcinol (CBD).
Pharmacokinetics
Administré par voie oromuqueuse (pulvérisation sous la langue ou sur la face interne de la joue), ce qui permet une absorption progressive des deux cannabinoïdes ; le THC et le CBD sont ensuite fortement métabolisés au niveau hépatique.
References
Structured data
- InChIKey
- SSNHGLKFJISNTR-DYSNNVSPSA-N
- SMILES
- CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
- Formula
- C42H60O4
- Molar mass
- 628.90 g·mol⁻¹
- CAS
- 56575-23-6
- PubChem CID
- 9852188
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.